Kasper Lykke
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy.
Journal: Neuropharmacology
Published: July 18, 2018
Cerebral influx of Na+ and Cl- as the osmotherapy-mediated rebound response in rats.
Journal: Fluids and barriers of the CNS
Published: June 08, 2018
Evaluating the involvement of cerebral microvascular endothelial Na+/K+-ATPase and Na+-K+-2Cl- co-transporter in electrolyte fluxes in an in vitro blood-brain barrier model of dehydration.
Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
Published: October 11, 2017
The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.
Journal: Epilepsy & behavior : E&B
Published: February 18, 2016
Vasopressin receptors V1a and V2 are not osmosensors.
Journal: Physiological reports
Published: August 28, 2015
Structure-activity relationships of bumetanide derivatives: correlation between diuretic activity in dogs and inhibition of the human NKCC2A transporter.
Journal: British journal of pharmacology
Published: January 15, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026